FINANCIAL RESULTS FOR 4TH QTR AND YEAR ENDED 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories Ltd reported audited standalone results for FY25 with zero revenue from operations, the same as FY24. Total expenses rose sharply to ₹13.71 lakhs from ₹1.64 lakhs, driven by higher employee costs (₹4.30 lakhs) and other expenses (₹9.41 lakhs). The company posted a net loss of ₹13.71 lakhs for the year versus a loss of ₹1.64 lakhs in FY24, marking a significant deterioration. The balance sheet shows total assets shrinking to ₹2.92 lakhs from ₹20.14 lakhs, equity deeply negative at (₹33.84 lakhs), and short-term borrowings jumping to ₹25.30 lakhs from ₹3.95 lakhs. Operating cash flow turned negative at (₹5.47 lakhs), and the auditor (Y. M. Shah & Co.) issued an unmodified opinion with no dividend recommended.
This is a deeply distressed micro-cap with no revenue, widening losses, negative net worth, and rising short-term debt. Shareholders should treat the stock as a high-risk penny stock — the company is essentially burning cash and relying on borrowings to stay afloat, which raises serious questions about its ability to continue as a going concern despite the clean audit report.